Raze Therapeutics is discovering the next generation of oncology therapeutics that target metabolic pathways essential to cancer growth and survival – one-carbon (1C) metabolism. The function of 1C metabolism is to drive rapid biomass accumulation. Using our proprietary platform, we are developing a pipeline of selective 1C metabolism therapeutics for specific solid and hematologic cancers. Raze was founded by scientific leaders in metabolism and cancer biology and is led by an experienced biotech management team.